MarketBeat
12 Sept 2026, 07:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Regeneron has completed repayment of its Sanofi development balance, meaning it will now record its full share of profits from DUPIXENT and KEVZARA. — This directly increases the company's reported earnings and cash flow from its highest-earning asset.
+0.60Regeneron is initiating pivotal studies for olatorepatide in obesity and type 2 diabetes. — Entry into the high-growth obesity and diabetes market represents a significant potential expansion of the total addressable market.
+0.50EYLEA HD now represents 60% of total EYLEA franchise sales, increasing from 50% in the previous quarter. — Rapid adoption of the high-dose version helps mitigate revenue erosion from upcoming EYLEA biosimilars.
+0.40Continue reading
5 related stories
Top 1 mover · tap to explore
The company targets FDA approval for an EYLEA HD prefilled syringe by the end of the year, despite facility issues at contract manufacturers. — Successful approval would improve delivery and competitive positioning, though facility issues introduce minor execution risk.
+0.30A PDUFA date is set for November for cemdisiran monotherapy in generalized myasthenia gravis. — Provides a near-term regulatory catalyst and a potential new revenue stream in neurology.
+0.20Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1d ago
